Halozyme Therapeutics

Compliant

Under AAOIFI Standard 21, Halozyme Therapeutics is compliant. Its core business is permissible and its interest-bearing debt is below 30% of market cap.

TickerHALO

ExchangeNASDAQ

SectorDrug Delivery Technology

Full ratios for Halozyme Therapeutics (impure revenue, debt and interest-bearing deposits under all four standards) are being added. Until then this page shows the screening verdict only. See the methodology for how each test works. Purindex publishes this screening to help people understand what they own. It does not recommend buying, selling or holding Halozyme Therapeutics or any other security.